: Cabozantinib improves survival in metastatic renal cell carcinoma (mRCC) after prior anti-angiogenics. The best treatment at disease progression (PD) is unknown. Being also a AXL/MET inhibitor, involved in acquired resistance, we hypothesized a prolonged tumor growth control in patients continuing cabozantinib despite PD.